Consultation Response on Proposed Framework for the Assessment of Biomarkers used in Cancer Care

BIOTECanada in collaboration with IMC submitted member input to Canada’s Drug Agency`s (CDA-AMC) consultation on the draft assessment framework intended to inform adoption or funding decisions on molecular, genetic, and genomic biomarker testing in cancer care. The submission highlighted clear opportunities to enhance system-wide preparedness for innovative diagnostic testing ensuring both improved health outcomes and greater equity in care, building health care infrastructure including reliable domestic supply, and positioning Canada to benefit from future research and development investments.